2024-11-12T10:59:47-06:00 2023-12-31 BDO USA 8401 GREENSBORO DRIVE 800 MCLEAN VA 22102 990 2023-01-01 311621592 INTERNATIONAL VACCINE INSTITUTE % SEUNGHWA CHEON INTE 8228722803 1 GWANAK-RO Gwanak-gu SEOUL KS FRANCOIS BELIN DEP DIR GENERAL, COO 7038930600 2024-11-08 true true JACOB COOK P01240455 7038930600 2024-11-08 2023 2024-10-15 13:58:12Z X JEROME H KIM 1 GWANAK-RO Gwanak-gu SEOUL KS 96582480 false X www.ivi.int X 1997 KS TO DISCOVER, DEVELOP AND DELIVER SAFE, EFFECTIVE AND AFFORDABLE VACCINES FOR GLOBAL PUBLIC HEALTH. ITS VISION IS DEVELOPING COUNTRIES FREE OF SUFFERING FROM INFECTIOUS DISEASE. 19 18 247 24 0 0 77015644 88351550 0 0 486502 1740857 -1344260 6490073 76157886 96582480 28444033 28723260 0 0 16444472 20028787 0 0 40888 17397711 28929969 62286216 77682016 13871670 18900464 86735648 104790256 6112540 5152214 80623108 99638042 X SEE SCHEDULE O false false 12830839 7280313 0 The goal of the GBP510 Phase III clinical trial is to show that the immune response generated by two doses of GBP510, administered 4 weeks apart in seronegative adults aged 18 and older, is superior or non-inferior to the response produced by two doses of ChAdOx1-S (AstraZeneca). Throughout 2023, the final participant visits were completed at all 22 study sites across five countries: Thailand, the Philippines, Vietnam, New Zealand, and Ukraine. Data cleaning was also finalized in preparation for the CSR. At the same time, the booster extension (Stage II) study progressed alongside the Phase III trial, with all seven visits successfully completed at two sites in Thailand. In May 2023, SK bioscience received Marketing Authorization of COVID-19 Vaccine from UK MHRA. https://www.skbioscience.com/en/news/news_01_01?mode=view&id=212& (30May2023) 2168101 1449309 0 VAT0008 is a pivotal multi-country phase 3, multi-stage, modified double-blind and multi-arm study where efficacy, safety and immunogenicity of two SARS-CoV-2 adjuvanted recombinant protein vaccines (monovalent and bivalent) were tested as primary series and monovalent booster dose as an extension. IVI led the effort in Nepal to conduct the clinical trial including conducting the local DSMB meeting. The primary series study was initiated in July 2021. The first subject for the primary series was enrolled in September 2021. The crossover/booster phase started in January 2023. The last subject vaccination for the crossover/booster phase was completed in November 2023. Investigators Meeting was conducted in February 2023 for the successful conduction of the primary series study. The 11th DSMB meeting was held on September 2023, and no safety concern was raised. IVI team conducted a Quality Control visit in Q3 2023. 1717072 907882 0 In 2023, the GCCDP team performed additional testing of a subgroup in Phase II samples at Nexelis laboratory in Canada after discussion with CEPI. Nexelis was chosen as the new central laboratory for all immunogenicity testing, following the decision to shift primary laboratory assay to micro-PRNT. The 3rd DSMB meeting was held in May 2023 upon completion all visits from Phase II, and DSMB endorsed the continuation of the studies as planned. Based on additional testing results of days 28 and 56 of Phase II subgroup samples, data from non-human primate (NHP) passive transfer study and safety data, a final decision on the optimal dose was made to 40 ug. A consortium consensus justification memo for final dose selection completed. Protocol Amendment V 5.0 containing this new information was approved by local Ethical Committees and NRAs. In Sep 2023, the proposal for expanding the program was submitted to CEPI to conduct the studies to assess the long-term safety, durability of protection and a measurement of vaccine effectiveness in Chikungunya virus endemic countries for the candidate CHIKV vaccine. 48259760 19085756 0 ALL OTHER PROGRAMS 48259760 19085756 0 64975772 true true false false false false false false false false true false false false true false true false false true true true false false true false false true false true false false false false false false false false false false false false false false false false false true X 0 0 247 true false true KS false false false false false false false false false false X 19 18 false false false false false true false true true false false false true true true true true true true false X SEUNGHWA CHEON 8228811167 1 gwanak-ro Gwanak-GU seoul KS JEROME KIM DIRECTOR GENERAL 40.0 0.0 X X 730385 0 149241 FRANCOIS BELIN CHIEF OPERATING OFFICER 40.0 0.0 X 476690 0 3494 FLORIAN MARKS DEPUTY DIR. GEN, EPIDEMIOLOGY 40.0 0.0 X 322094 0 1910 ANH WARTEL DEPUTY DIR. GEN, EUROPE 40.0 0.0 X 315282 0 2279 SUSHANT SAHASTRABUDDHE ASSOCIATE DIRECTOR GENERAL 40.0 0.0 X 301836 0 2933 JULIA LYNCH PROGRAM DIRECTOR, CHOLERA 40.0 0.0 X 286139 0 16489 JOHN D CLEMENS SENIOR SCIENTIFIC ADVISOR 40.0 0.0 X 258979 0 40817 MANKI SONG DEPUTY DIR. GENERAL, SCIENCE 40.0 0.0 X 284147 0 3735 Tobin Guarnacci Global Head, Quality Mgmt 40.0 0.0 X 253255 0 24699 Vincent Canouet DEPUTY DIR. GEN, Strategy 40.0 0.0 X 252723 0 718 Kyung-Taik Han DEPUTY DIR. GEN, Gov. Relation 40.0 0.0 X 239087 0 1130 Jean-Louis Excler Program Dir., New Initiatives 40.0 0.0 X 218092 0 520 GEORGE BICKERSTAFF CHAIRPERSON / BOARD OF TRUSTEE 1.0 0.0 X 1500 0 0 HANNAH NOHYNEK VICE-CHAIRPERSON/BOARD TRUSTEE 1.0 0.0 X 1500 0 0 MALCOLM SWEENEY THRU 1123 TREASURER / BOARD OF TRUSTEE 1.0 0.0 X 1500 0 0 ZIAD AHMED A MEMISH DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 1500 0 0 MELANIE SAVILLE DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 1500 0 0 RALF CLEMENS DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 1250 0 0 ANTHONY FORD-HUTCHINSON DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 1250 0 0 JEAN-MARIE OKWO-BELE DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 1000 0 0 CHRIS VARMA thru 1123 DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 1000 0 0 YANCHUN LILY LI as of 1123 DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 750 0 0 RICHARD HENRIQUESas of 1123 DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 750 0 0 GORDON DOUGAN DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 500 0 0 RAJIV BAHL DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 Jos R-Estupian THRU 1023 DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 EHSANUL KABIR DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 JOO-YOEN KANG DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 Takeshi Kasai thru 0323 DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 OUTI KUIVASNIEMI DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 LEON MUTESA DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 NAKORN PREMSRI DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 GI-EUN RHIE DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 KIM SUNG SOON THRU 0323 DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 CATHARINA MAIJGREN STEFFENSSO DIRECTOR / BOARD OF TRUSTEE 1.0 0.0 X 0 0 0 3952709 0 247965 50 false true false 0 58998 28950768 59341784 88351550 0 1740857 1740857 0 0 0 0 0 0 0 58998 0 0 0 0 0 0 0 0 0 FOREIGN EXCHANGE LOSS 900099 -78912 -78912 RENTAL FOR RESEARCH COLLABORATION 900099 56947 56947 RENTAL FOR ANIMAL ROOM 900099 41129 41129 6470909 6470909 6490073 96582480 8230930 1980911 1980911 0 26742349 26742349 0 2796915 1812481 984434 0 0 15335639 10687904 4647735 0 1083679 767377 316302 0 584873 351078 233795 0 227681 143227 84454 0 0 137472 30851 106621 0 75376 15127 60249 0 0 0 0 4994605 3954276 1040329 0 0 2620452 2432142 188153 157 1140986 648973 484646 7367 0 2222293 63424 2158869 0 3633535 2996500 636606 429 0 713184 544600 136128 32456 0 0 1388350 104426 1283924 0 46613 22869 23744 0 LAB SUPPLIES 4010703 3889285 121418 0 TRAINING 354597 303055 51542 0 REPAIRS AND MAINTENANCE 85304 12998 72306 0 OTHER EXPENSES 7506499 7471919 34101 479 77682016 64975772 12665356 40888 0 0 54790470 57393380 0 0 11534313 25510041 0 0 0 0 0 0 0 0 463818 531156 17292623 9046554 6641155 8246069 0 0 0 0 0 0 12659544 12300408 646348 809202 86735648 104790256 6060979 5102041 0 0 0 0 0 0 0 0 0 0 0 0 0 0 51561 50173 6112540 5152214 X 41002574 50192934 39620534 49445108 80623108 99638042 86735648 104790256 X 18900464 114470 X false true X true false X 30794801 51411216 52941661 77015644 88351550 300514872 0 0 30794801 51411216 52941661 77015644 88351550 300514872 122850231 177664641 380381 126251 56420 486502 1740857 2790411 0 143408 2347736 0 0 6490073 8981217 312286500 69 0.56892 0.56822 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1195955 261606 934349 16053304 8741585 7311719 43364 43363 1 8246069 0 SECURITY DEPOSIT 50173 50173 92595403 92595403 3987077 3987077 96582480 73580469 -4101547 -4101547 77682016 77682016 SCHEDULE D, PART XI, LINE 4B: FOREIGN EXCHANGE LOSS $-2,468,941 OVERHEAD RELEASED $6,456,018 SCHEDULE D, PART XII, LINE 2D: FOREIGN EXCHANGE LOSS $2,468,941 OVERHEAD RELEASED $-6,456,018 PRIOR YEAR GRANT REVERSAL $-114,470 true East Asia and the Pacific 7 30 Program Services Program Services 8916369 Europe (Including Iceland and Greenland) 9 19 Program Services Program Services 5557688 South Asia 4 17 Program Services Program Services 5348699 Sub-Saharan Africa 10 18 Program Services Program Services 4157258 South America 1 3 Program Services Program Services 1154293 North America 2 3 Program Services Program Services 912820 Central America and the Caribbean 3 4 Program Services Program Services 695222 36 94 36 94 26742349 26742349 East Asia & the Pacific 5260416 Wire Europe (Including Iceland and Greenland) 2065644 Wire Europe (Including Iceland and Greenland) 1405579 Wire Sub-Saharan Africa 1220976 Wire South Asia 974918 Wire South Asia 830836 Wire East Asia & the Pacific 800000 Wire South America 658191 Wire South Asia 645978 Wire North America 603770 Wire Central America & Caribbean 553532 Wire South Asia 531845 Wire South Asia 466223 Wire East Asia & the Pacific 460822 Wire East Asia & the Pacific 401670 Wire South America 399998 Wire Sub-Saharan Africa 381105 Wire Sub-Saharan Africa 379128 Wire Sub-Saharan Africa 361359 Wire Sub-Saharan Africa 344507 Wire Europe (Including Iceland and Greenland) 341468 Wire Sub-Saharan Africa 340000 Wire Europe (Including Iceland and Greenland) 327884 Wire Europe (Including Iceland and Greenland) 310000 Wire South Asia 288288 Wire Sub-Saharan Africa 284971 Wire North America 280957 Wire South Asia 260000 Wire Sub-Saharan Africa 250000 Wire South Asia 249817 Wire South Asia 249169 Wire South Asia 232400 Wire Europe (Including Iceland and Greenland) 222455 Wire East Asia & the Pacific 215000 Wire East Asia & the Pacific 203000 Wire Sub-Saharan Africa 202945 Wire Europe (Including Iceland and Greenland) 193305 Wire South Asia 173908 Wire East Asia & the Pacific 168292 Wire Europe (Including Iceland and Greenland) 158298 Wire East Asia & the Pacific 148144 Wire East Asia & the Pacific 135000 Wire South Asia 125390 Wire Europe (Including Iceland and Greenland) 123142 Wire South Asia 120000 Wire Sub-Saharan Africa 114891 Wire East Asia & the Pacific 109307 Wire East Asia & the Pacific 107297 Wire Europe (Including Iceland and Greenland) 100000 Wire East Asia & the Pacific 97091 Wire East Asia & the Pacific 88300 Wire Sub-Saharan Africa 78895 Wire East Asia & the Pacific 76932 Wire Central America & Caribbean 76690 Wire Europe (Including Iceland and Greenland) 74259 Wire South Asia 73221 Wire East Asia & the Pacific 71623 Wire South Asia 67500 Wire South America 62851 Wire East Asia & the Pacific 62752 Wire East Asia & the Pacific 53926 Wire Sub-Saharan Africa 52402 Wire East Asia & the Pacific 50741 Wire Central America & Caribbean 50000 Wire East Asia & the Pacific 46371 Wire East Asia & the Pacific 46371 Wire East Asia & the Pacific 45000 Wire East Asia & the Pacific 41271 Wire Europe (Including Iceland and Greenland) 38912 Wire Europe (Including Iceland and Greenland) 38842 Wire East Asia & the Pacific 37956 Wire East Asia & the Pacific 37845 Wire Europe (Including Iceland and Greenland) 35624 Wire South Asia 34205 Wire East Asia & the Pacific 33122 Wire South America 32328 Wire Sub-Saharan Africa 31117 Wire Europe (Including Iceland and Greenland) 30666 Wire Europe (Including Iceland and Greenland) 30343 Wire North America 28094 Wire Sub-Saharan Africa 26159 Wire Sub-Saharan Africa 25896 Wire South Asia 25000 Wire Europe (Including Iceland and Greenland) 23609 Wire Sub-Saharan Africa 21316 Wire Sub-Saharan Africa 20756 Wire Europe (Including Iceland and Greenland) 20000 Wire Sub-Saharan Africa 17229 Wire East Asia & the Pacific 17067 Wire East Asia & the Pacific 16935 Wire East Asia & the Pacific 16726 Wire East Asia & the Pacific 16022 Wire Central America & Caribbean 15000 Wire Europe (Including Iceland and Greenland) 13301 Wire East Asia & the Pacific 12146 Wire East Asia & the Pacific 8888 Wire East Asia & the Pacific 6067 Wire East Asia & the Pacific 5246 Wire 17 81 false false false false false false SCHEDULE F, PART I, LINE 2: THE IVI IS LOCATED IN SEOUL, KOREA WHERE ALL THE GRANT FUNDS ARE MANAGED AND EXECUTED. THE IVI HAS IN PLACE A VERY DETAILED AND RIGOROUS SYSTEM OF FINANCIAL MONITORING. THIS SYSTEM, WHICH IS EVALUATED BY INTERNAL FINANCE PERSONNEL THROUGHOUT THE YEAR AND AUDITED EXTERNALLY EVERY YEAR, IS USED IN CONJUNCTION WITH CAREFUL PROJECT DEVELOPMENT AND IMPLEMENTATION TO ENSURE ACCOUNTABILITY AND BUDGETARY MANAGEMENT RESPONSIBILITY. FOR SUBGRANTS, THE IVI HAS A BROAD OVERALL SYSTEM OF REVIEWING AND TRACKING THE USE OF GRANTS, AND MORE SPECIFIC DAY-TO-DAY REVIEW PROCESSES, WHICH INCLUDE THE FOLLOWING: -REVIEWS OF FINANCIAL AND NARRATIVE REPORTS, AUDIT REPORTS, CORRESPONDENCE AND OTHER DOCUMENTATION PROVIDED BY THE GRANTEES -DIRECT COMMUNICATION WITH GRANTEES THROUGH TELEPHONE AND EMAIL FOR QUESTIONS AND TO CHECK ON PROGRESS OF THE PROJECT -ON-SITE VISITS TO THE FIELD SITES TO REVIEW ONE OR MORE ASPECTS OF THE PROJECTS -MONITORING THROUGH AN EXTERNAL AUDIT. A CERTAIN NUMBER OF SUB-GRANTEES ARE SELECTED FOR THE AUDIT EACH YEAR, WHICH IS DONE TO ENSURE FINANCIAL AND EXPENDITURE COMPLIANCE WITH THE RESEARCH AGREEMENT. SPECIAL EVENT 58998 58998 0 0 0 0 0 0 0 58998 58998 0 0 0 0 0 0 0 0 true ICON Government and Public Health Solutions Inc 31 Arbor Way Suite 100 Blue Bell PA 19422 541716562 GOV'T 886866 Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Service Program Texas Tech University Health Science 3601 4th ST Lubbock TX 794306209 752142549 501(c)(3) 285000 EdJen BioTech LLC 641 Lexington Ave 13th Fl NY NY 10022 N/A 235000 SAIL FOR HEALTH LLC 16192 Coastal Highway Lewes DE 19958 N/A 193108 President and Fellows of Harvard College Massachusetts Hall Cambridge MA 02138 042103580 501(c)(3) 164643 University of Maryland College Park College Park MD 20742 526002033 Maryland State 60000 Brigham and Women's Hospital 15 Francis St Boston MA 02115 550916227 501(c)(3) 41099 University of Washington Northeast Seattle Seattle WA 9819 Seattle WA 98195 916001537 170(c)(1) 40000 Public Health Surveillance Group LLC 300 Carnegie Center Princeton NJ 08540 311621592 N/A 27793 Levin & Morgan LLC (Ann Levin) 6414 Hollins Dr Bethesda MD 20817 Carolina MD 20817 N/A 20000 Veristat LLC 134 Turnpike Road SouthboroughMA Morrisville MA 01772 N/A 18342 Massachusetts General Hospital 55 Fruit Street Boston MA 021142696 041564655 501(c)(3) 8417 7 5 SCHEDULE I, PART I, LINE 2: THE IVI IS LOCATED IN SEOUL, KOREA WHERE ALL THE GRANT FUNDS ARE MANAGED AND EXECUTED. THE IVI HAS IN PLACE A VERY DETAILED AND RIGOROUS SYSTEM OF FINANCIAL MONITORING. THIS SYSTEM, WHICH IS EVALUATED BY INTERNAL FINANCE PERSONNEL THROUGHOUT THE YEAR AND AUDITED EXTERNALLY EVERY YEAR, IS USED IN CONJUNCTION WITH CAREFUL PROJECT DEVELOPMENT AND IMPLEMENTATION TO ENSURE ACCOUNTABILITY AND BUDGETARY MANAGEMENT RESPONSIBILITY. FOR SUBGRANTS, THE IVI HAS A BROAD OVERALL SYSTEM OF REVIEWING AND TRACKING THE USE OF GRANTS, AND MORE SPECIFIC DAY-TO-DAY REVIEW PROCESSES, WHICH INCLUDE THE FOLLOWING: -REVIEWS OF FINANCIAL AND NARRATIVE REPORTS, AUDIT REPORTS, CORRESPONDENCE AND OTHER DOCUMENTATION PROVIDED BY THE GRANTEES -DIRECT COMMUNICATION WITH GRANTEES THROUGH TELEPHONE AND EMAIL FOR QUESTIONS AND TO CHECK ON PROGRESS OF THE PROJECT -ON-SITE VISITS TO THE FIELD SITES TO REVIEW ONE OR MORE ASPECTS OF THE PROJECTS -MONITORING THROUGH AN EXTERNAL AUDIT. A CERTAIN NUMBER OF SUB-GRANTEES ARE SELECTED FOR THE AUDIT EACH YEAR, WHICH IS DONE TO ENSURE FINANCIAL AND EXPENDITURE COMPLIANCE WITH THE RESEARCH AGREEMENT. X X X X true true X X X X false false false false false false false false false JEROME KIM DIRECTOR GENERAL 385911 0 66915 0 277559 0 148500 0 741 0 879626 0 0 0 FRANCOIS BELIN CHIEF OPERATING OFFICER 349858 0 0 0 126832 0 0 0 3494 0 480184 0 0 0 FLORIAN MARKS DEPUTY DIR. GEN, EPIDEMIOLOGY 258628 0 0 0 63466 0 0 0 1910 0 324004 0 0 0 ANH WARTEL DEPUTY DIR. GEN, EUROPE 244330 0 0 0 70952 0 0 0 2279 0 317561 0 0 0 SUSHANT SAHASTRABUDDHE ASSOCIATE DIRECTOR GENERAL 187803 0 0 0 114033 0 0 0 2933 0 304769 0 0 0 JULIA LYNCH PROGRAM DIRECTOR, CHOLERA 242846 0 0 0 43293 0 0 0 16489 0 302628 0 0 0 JOHN D CLEMENS SENIOR SCIENTIFIC ADVISOR 241041 0 0 0 17938 0 40000 0 817 0 299796 0 0 0 MANKI SONG DEPUTY DIR. GENERAL, SCIENCE 229156 0 0 0 54991 0 2365 0 1370 0 287882 0 0 0 Tobin Guarnacci Global Head, Quality Mgmt 181788 0 0 0 71467 0 20000 0 4699 0 277954 0 0 0 Vincent Canouet DEPUTY DIR. GEN, Strategy 188975 0 0 0 63748 0 0 0 718 0 253441 0 0 0 Kyung-Taik Han DEPUTY DIR. GEN, Gov. Relation 196116 0 0 0 42971 0 0 0 1130 0 240217 0 0 0 Jean-Louis Excler Program Dir., New Initiatives 218092 0 0 0 0 0 0 0 520 0 218612 0 0 0 SCHEDULE J, PART I, LINE 1A: TRAVEL FOR COMPANION: AFTER 15 MONTHS OF SERVICE, THE INTERNATIONALLY RECRUITED STAFF IS ENTITLED TO HOME LEAVE TRAVEL. THIS ENTITLEMENT IS AN ECONOMY ROUND TRIP BETWEEN DUTY STATION AND HOME BASE FOR STAFF, SPOUSE AND DEPENDENTS UNDER 21. TAX INDEMNIFICATION AND GROSS UP PAYMENTS: IN ORDER TO EQUALIZE THE BENEFITS ACCRUED TO INTERNATIONALLY RECRUITED STAFF, IVI COMPENSATES STAFF WHO ARE OBLIGATED TO PAY TAXES ON IVI DERIVED INCOME TO THEIR HOME COUNTRY. ANY TAX SUBSEQUENTLY LEVIED ON THE AMOUNT OF THE REIMBURSEMENT IS NOT REIMBURSED. IN GENERAL, THIS IS TREATED AS TAXABLE COMPENSATION. HOUSING ALLOWANCE: IVI PROVIDES INTERNATIONALLY RECRUITED STAFF IN KOREA WITH A HOUSING ALLOWANCE UP TO 75% OF A CEILING THAT IS ESTABLISHED AND REVIEWED PERIODICALLY. PERSONAL SERVICES (I.E. DRIVER): IVI PROVIDES THE DIRECTOR GENERAL WITH A DRIVER WHICH IS INCLUDED IN HIS/HER EMPLOYMENT CONTRACT PACKAGE APPROVED BY THE BOARD OF TRUSTEES. FORM 990, PART III, LINE 1: IVI IS THE ONLY INTERNATIONAL ORGANIZATION IN THE WORLD EXCLUSIVELY DEDICATED TO DISCOVERING, DEVELOPING AND DELIVERING VACCINES FOR GLOBAL HEALTH. IVI FOCUSES ON VACCINES AGAINST INFECTIOUS DISEASES OF THE MOST IMPOVERISHED. WE AIM TO MAKE VACCINES AVAILABLE AND ACCESSIBLE FOR VULNERABLE POPULATIONS IN DEVELOPING COUNTRIES. WE LIVE IN AN INCREASINGLY GLOBALIZED WORLD WHERE NEW AND EMERGING INFECTIOUS DISEASES CAN BECOME GLOBAL HEALTH THREATS. IVI ALSO FOCUSES ON VACCINES AGAINST INFECTIOUS DISEASES OF MAJOR GLOBAL HEALTH CONCERN. OUR RESEARCH SPANS THE ENTIRE VACCINE SPECTRUM FROM DISCOVERY AND PRECLINICAL DEVELOPMENT IN OUR SEOUL-BASED LABS TO CLINICAL DEVELOPMENT AT FIELD SITES IN DEVELOPING COUNTRIES TO GENERATING SCIENTIFIC EVIDENCE ON THE NEED FOR VACCINATION IN COUNTRIES WHERE VACCINES ARE MOST NEEDED. OUR HEADQUARTERS IN SEOUL HAVE STATE-OF-THE ART LAB FACILITIES, ANIMAL HOUSE, AND RESEARCH TEAMS THAT INCLUDE CLINICAL IMMUNOLOGY, PROCESS DEVELOPMENT, EPIDEMIOLOGY, CLINICAL & REGULATORY, BIOSTATISTICS & DATA MANAGEMENT, AND POLICY & ECONOMIC RESEARCH. OUTSIDE OF SEOUL, WE HAVE A GLOBAL NETWORK OF FIELD SITES IN MORE THAN 20 COUNTRIES IN ASIA, AFRICA, AND THE AMERICAS. WE MANAGE FIELD SITES IN COLLABORATION WITH REGIONAL AND IN-COUNTRY PARTNERS. WE WORK WITH LOCAL PARTNERS TO IMPLEMENT TRANSLATIONAL AND FIELD RESEARCH PROJECTS, AND WE ALSO PROVIDE TRAINING AND TECHNICAL ASSISTANCE. FORM 990, PART V, LINES 1A AND 2A: IVI'S HEADQUARTERS IS BASED IN SEOUL, KOREA. SINCE THE ORGANIZATION IS NOT UNITED STATES BASED, THE ORGANIZATION HAS ONLY FILED (2) FORM W-2s FOR EMPLOYEES RESIDING IN THE UNITED STATES. AS OF DECEMBER 31, 2023, THE ORGANIZATION REPORTS 247 EMPLOYEES. FORM 990, PART V, LINE 4: IVI IS A FOREIGN ORGANIZATION. IT IS NOT REQUIRED TO FILE FORM FINCEN 114 (REPORT OF FOREIGN BANK AND FINANCIAL ACCOUNTS). FORM 990, PART VI, LINE 7A: THE DIRECTOR GENERAL OF THE INSTITUTE IS ALSO A VOTING MEMBER OF THE BOARD; THUS, HE/SHE CAN PARTICIPATE IN THE ELECTION OF THE BOARD. FORM 990, PART VI, LINE 11B: THE FINANCE TEAM MAKES A FIRST DRAFT OF FORM 990 AND THE RELATED SCHEDULES. HR PROVIDES SPECIFIC INFORMATION ON COMPENSATION AND OTHER TEAMS PROVIDE FUNDRAISING, GOVERNANCE AND MANAGEMENT INFORMATION. PUBLIC ACCOUNTANT PREPARES THE RETURN ON IVI'S BEHALF AND THIS IS REVIEWED IN TURN BY THE COO AND HEAD OF FINANCE FOR ACCURACY. FORM 990, PART VI, LINE 12C: THE IVI HR PROVIDES A COPY OF THE CONFLICT OF INTEREST POLICY TO ALL DIRECTORS, OFFICERS AND STAFF TO REVIEW AND COMPLETE A DECLARATION OF CONFLICT OF INTEREST ANNUALLY. IN CONNECTION WITH ANY ACTUAL OR POTENTIAL CONFLICT OF INTEREST, EACH INTERESTED PERSON MUST DISCLOSE THE EXISTENCE OF HIS OR HER SIGNIFICANT FINANCIAL INTERESTS, SIGNIFICANT EQUITY INTERESTS, INTELLECTUAL PROPERTY INTERESTS OR OUTSIDE INTERESTS TO THE CONFLICT COORDINATOR (DIRECTOR GENERAL) WHO MAY CREATE A CONFLICT COMMITTEE COMPOSED OF THREE OTHER MEMBERS OF THE IVI STAFF TO REVIEW CONFLICT OF INTEREST ISSUES THAT MAY ARISE. THE CONFLICT COMMITTEE SHALL BE RESPONSIBLE FOR ENSURING THAT RELEVANT CONFLICTS OF INTEREST, AND THE PROCEDURES TAKEN TO ELIMINATE, REDUCE OR MANAGE THOSE CONFLICTS, ARE DISCLOSED AT OR PRIOR TO ANY BOARD OF TRUSTEES MEETING. THE COMMITTEE SHALL KEEP A RECORD OF ALL ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AND REPORT ANNUALLY THEREON TO THE BOARD OF TRUSTEES. IN CASE OF TRUSTEES, IVI BOARD SECRETARIAT PROVIDES A COPY OF THE CONFLICT OF INTEREST POLICY TO THE MEMBERS WHEN THEY FIRST JOIN, ALL MEMBERS MUST SUBMIT A SIGNED COPY OF THE DISCLOSURE OF ACTUAL AND POTENTIAL CONFLICTS OF INTEREST TO IVI. THE MEMBERS SHOULD REPORT THEIR CHANGES OF STATUS TO THE BOARD SECRETARIAT. FORM 990, PART VI, LINES 15A AND 15B: THE IVI UNDERTAKES A COMPREHENSIVE COMPENSATION STUDY FOR ITS TOP MANAGEMENT OFFICIAL, OFFICERS AND KEY EMPLOYEES. A COMPENSATION CONSULTANT CONDUCTS THE STUDY AND LOOKS AT COMPENSATION AMONG COMPARABLE ORGANIZATIONS WITH SIMILAR POSITIONS AND RESPONSIBILITIES IN ORDER TO PROVIDE MARKET DATA TO DETERMINE IVI STAFF MEMBER COMPENSATION. COMPENSATION IS SET BY INDEPENDENT PERSONS, AND CONTEMPORANEOUS DOCUMENTATION OF THE PROCESS IS RETAINED. FORM 990, PART VI, LINE 19: THE IVI'S GOVERNING DOCUMENTS-ESTABLISHMENT AGREEMENT, HEADQUARTERS AGREEMENT, CONSTITUTION AND AMENDMENTS TO THE CONSTITUTION ARE AVAILABLE ON IVI'S WEBSITE. THE SUMMARY OF FINANCIAL REPORT IS INCLUDED IN IVI'S ANNUAL REPORT. THE AUDIT REPORT IS ALSO SHARED ON IVI'S WEBSITE. FORM 990, PART XI, LINE 9: PRIOR YEAR GRANT REVERSAL: 114,470